BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30257642)

  • 1. Salivary beta amyloid protein levels are detectable and differentiate patients with Alzheimer's disease dementia from normal controls: preliminary findings.
    Sabbagh MN; Shi J; Lee M; Arnold L; Al-Hasan Y; Heim J; McGeer P
    BMC Neurol; 2018 Sep; 18(1):155. PubMed ID: 30257642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Method for Diagnosing Alzheimer's Disease Based on Salivary Amyloid-β Protein 42 Levels.
    Lee M; Guo JP; Kennedy K; McGeer EG; McGeer PL
    J Alzheimers Dis; 2017; 55(3):1175-1182. PubMed ID: 27792013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study.
    Bermejo-Pareja F; Antequera D; Vargas T; Molina JA; Carro E
    BMC Neurol; 2010 Nov; 10():108. PubMed ID: 21047401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saliva, an easily accessible fluid as diagnostic tool and potent stem cell source for Alzheimer's Disease: Present and future applications.
    Reale M; Gonzales-Portillo I; Borlongan CV
    Brain Res; 2020 Jan; 1727():146535. PubMed ID: 31669827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salivary Aβ
    Fan Z; Li Z; Zhao S; Chen Y; Su Y; Peng G; Luo B
    J Neurol; 2023 Apr; 270(4):1945-1954. PubMed ID: 36562850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between the diagnosis method of neuronal dysfunction (DIMENSION) and brain pathology in the early stages of Alzheimer's disease.
    Kouzuki M; Asaina F; Taniguchi M; Musha T; Urakami K
    Psychogeriatrics; 2013 Jun; 13(2):63-70. PubMed ID: 23909962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-based magnetic nanoparticle immunoassay for quantification of Alzheimer's disease pathogenic factor.
    Kim CB; Choi YY; Song WK; Song KB
    J Biomed Opt; 2014 May; 19(5):051205. PubMed ID: 24297060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive function in very old men does not correlate to biomarkers of Alzheimer's disease.
    Velickaite V; Giedraitis V; Ström K; Alafuzoff I; Zetterberg H; Lannfelt L; Kilander L; Larsson EM; Ingelsson M
    BMC Geriatr; 2017 Sep; 17(1):208. PubMed ID: 28886705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
    Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
    JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease.
    Wang T; Xiao S; Liu Y; Lin Z; Su N; Li X; Li G; Zhang M; Fang Y
    Int J Geriatr Psychiatry; 2014 Jul; 29(7):713-9. PubMed ID: 24318929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function.
    Kettunen P; Larsson S; Holmgren S; Olsson S; Minthon L; Zetterberg H; Blennow K; Nilsson S; Sjölander A
    J Alzheimers Dis; 2015; 44(4):1313-22. PubMed ID: 25420549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
    Barthel H; Gertz HJ; Dresel S; Peters O; Bartenstein P; Buerger K; Hiemeyer F; Wittemer-Rump SM; Seibyl J; Reininger C; Sabri O;
    Lancet Neurol; 2011 May; 10(5):424-35. PubMed ID: 21481640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Systematic Review on the Feasibility of Salivary Biomarkers for Alzheimer's Disease.
    Bouftas M
    J Prev Alzheimers Dis; 2021; 8(1):84-91. PubMed ID: 33336229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease.
    Kristofikova Z; Ricny J; Kolarova M; Vyhnalek M; Hort J; Laczo J; Sirova J; Ripova D
    J Alzheimers Dis; 2014; 42 Suppl 3():S91-8. PubMed ID: 24670397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.
    Jongbloed W; Bruggink KA; Kester MI; Visser PJ; Scheltens P; Blankenstein MA; Verbeek MM; Teunissen CE; Veerhuis R
    J Alzheimers Dis; 2015; 45(1):35-43. PubMed ID: 25547634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of serum β-amyloid peptides, α2-macroglobulin, complement factor H, and clusterin levels in APP/PS1 transgenic mice during progression of Alzheimer's disease.
    Wang D; Di X; Fu L; Li Y; Han X; Wu H; Cai L; Meng X; Jiang C; Kong W; Su W
    Neuroreport; 2016 Oct; 27(15):1114-9. PubMed ID: 27541273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.